A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
NCT06898450
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
134
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors Cancer
MSI-H Cancer
Interventions
DRUG:
NDI-219216
Sponsor
Nimbus Wadjet, Inc.
Collaborators
Worldwide Clinical Trials